Osteoarthritis Gene Therapy Sector: Growth Drivers and Challenges
Growth Drivers
-
Rising Cases of Osteoarthritis Among Global Population
-
Low-Cost Medication Available
- Growing Geriatric Population with Hip and Knee Disorders
Challenges
-
The Consumption of NSAIDs Leading to a High CVD Risk in Patients
Osteoarthritis Gene Therapy Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.9% |
|
Base Year Market Size (2024) |
USD 8.07 billion |
|
Forecast Year Market Size (2037) |
USD 21.68 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of osteoarthritis gene therapy is estimated at USD 8.61 billion.
Osteoarthritis Gene Therapy Market size was valued at USD 8.07 billion in 2024 and is likely to cross USD 21.68 billion by 2037, expanding at more than 7.9% CAGR during the forecast period i.e., between 2025-2037.
Europe industry is estimated to dominate majority revenue share by 2037, on the back of increasing geriatric population with osteoarthritis disease.
The major players in the market are Sanofi-aventis Groupe, Horizon Therapeutics plc, Hanmi Pharm. Co., Ltd., ALMATICA PHARMA LLC., Assertio Holdings, Inc., Flexion Therapeutic, Inc., Zimmer Biomet Holdings, Inc., Pfizer Inc., and others.
